dioleoyl phosphatidylethanolamine | 20707-71-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: dioleoyl phosphatidylethanolamine
• 英文别名: 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine；DOPE；PE-C18:2/C18:2；DLOPE；L-(+)-Dilinoleoyl-α-kephalin；1,2-Dilinoleoyl-sn-glycero-3-phosphoethanolamine zwitterion；2-azaniumylethyl [(2R)-2,3-bis[[(9Z,12Z)-octadeca-9,12-dienoyl]oxy]propyl] phosphate
• CAS: 20707-71-5
• 化学式: C₄₁H₇₄NO₈P
• 分子量: 740.014
• InChiKey: SSCDRSKJTAQNNB-DWEQTYCFSA-N

物化性质

• 沸点：
  758.4±70.0 °C(Predicted)
• 密度：
  1.020±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  51
• 可旋转键数：
  39
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  dioleoyl phosphatidylethanolamine 在 platinum(IV) oxide 氢气 作用下， 生成 1,2二硬酯酸-3磷脂酰乙醇胺
  参考文献：
  名称：

  Dorofeeva,L.T. et al., Journal of general chemistry of the USSR, 1963, vol. 33, p. 2807 - 2809

  摘要：

  DOI：
• 作为产物：
  描述：

  L-(+)-Dilinoleoyl-N-phthaloyl-α-kephalin 在 sodium hydroxide 、 一水合肼 作用下， 生成 dioleoyl phosphatidylethanolamine
  参考文献：
  名称：

  Dorofeeva,L.T. et al., Journal of general chemistry of the USSR, 1963, vol. 33, p. 2807 - 2809

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR L'ADMINISTRATION INTRACELLULAIRE D'AGENTS
  申请人：MODERNATX INC

  公开号：WO2018232120A1

  公开（公告）日：2018-12-20

  The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

  该披露涉及氨基脂质和包含氨基脂质的组合物。纳米粒子组合物包括氨基脂质以及额外的脂质，如磷脂、结构脂质、PEG脂质或二者的组合。纳米粒子组合物还包括治疗和/或预防剂，如RNA，可用于将治疗和/或预防剂传递到哺乳动物细胞或器官，例如，调节多肽、蛋白质或基因表达。
• NANOMATERIALS
  申请人：Guide Therapeutics, Inc.

  公开号：US20210169804A1

  公开（公告）日：2021-06-10

  Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo without the need for a targeting ligand.

  描述了用于传递核酸的脂质纳米粒子组合物。脂质纳米粒子可能包含作为组合物的一部分的构象受限的可离子化脂质。这些组合物可能允许传递货物而无需靶向配体。
• [EN] BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS<br/>[FR] MOLÉCULES DE PEG RAMIFIÉ, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：PHASERX INC

  公开号：WO2018126084A1

  公开（公告）日：2018-07-05

  Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.

  揭示了分支聚乙二醇（PEG）分子，包括分支PEG-脂质和分支PEG-蛋白质，以及制备分支PEG分子的相关组合物和方法。还公开了相关的组合物、系统和方法，用于体内传递治疗和诊断试剂。
• [EN] COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY<br/>[FR] COMPOSITIONS ET MÉTHODES D'ADMINISTRATION CIBLÉE D'ARN
  申请人：VERVE THERAPEUTICS INC

  公开号：WO2021178725A1

  公开（公告）日：2021-09-10

  Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.

  本文提供了组合物、制备方法以及用于靶向传递治疗剂以修改靶基因表达和功能的方法，例如涉及脂质和胆固醇代谢的蛋白质，如PCSK9。此外，还提供了与冠心病相关疾病的治疗组合物和方法。
• [EN] COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR L'ADMINISTRATION INTRACELLULAIRE D'AGENTS THÉRAPEUTIQUES ET/OU PROPHYLACTIQUES
  申请人：MODERNATX INC

  公开号：WO2017112865A1

  公开（公告）日：2017-06-29

  The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

  该披露涉及氨基脂质和相关组合物。纳米粒子组合物包括氨基脂质以及额外的脂质，如磷脂、结构脂质、PEG脂质或二者的组合。纳米粒子组合物还包括治疗和/或预防剂，如RNA，可用于将治疗和/或预防剂传递至哺乳动物细胞或器官，例如，调节多肽、蛋白质或基因表达。